Surinabant

• CAT Number: I009653
• CAS Number: 288104-79-0
• Molecular Formula: C23H23BrCl2N4O
• Molecular Weight: 522.27
• Purity: ≥95%
• Synonyms: SR-147778; SR147778; SR 147778;5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide
• Target: cannabinoid CB1 antagonist
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
• InChI: InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)
• InChIKey: HMXDWDSNPRNUKI-UHFFFAOYSA-N
• SMILES: CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br

Surinabant（Cat No.:I009653）is a selective antagonist of the cannabinoid receptor type 1 (CB1), a receptor involved in regulating appetite, metabolism, and various neurological functions. By blocking the CB1 receptor, surinabant can reduce appetite and potentially aid in weight management. It has been explored in clinical trials as a treatment for obesity and metabolic disorders. Additionally, surinabant has been investigated for its potential benefits in addressing neurological conditions such as anxiety and depression. However, despite its promising effects in early research, its development has been halted due to safety concerns and side effects related to psychiatric symptoms.